Medicines labeled for the same conditions
Alternatives to gemcitabine
14 other medicines are given the same way (intravenous) and in the same FDA class as gemcitabine or labeled mainly for the same use (breast cancer); the others include 4 her2/neu receptor antagonists, 3 microtubule inhibitors and 1 programmed death receptor-1 blocking antibody (FDA labels read October 8, 2026).
Which medicines are labeled for the same conditions as gemcitabine?
Breast cancer lists all 44 medicines labeled for it, by any route. Each row shows the conditions both labels name. They are listed as public records, not as substitutes: whether one can replace another depends on the person and is a prescriber's decision.
| Medicine and FDA class | Shared indication | Generic labelers (intravenous) | Pharmacy cost | Boxed warning | Shortage |
|---|---|---|---|---|---|
| Gemcitabinenucleoside metabolic inhibitor | this medicine | 10 labelers | n/a | No | No current entry |
| Docetaxelmicrotubule inhibitor | Breast cancer, Lung cancer | 14 labelers | n/a | Yes | A presentation being discontinued |
| Paclitaxelmicrotubule inhibitor | Breast cancer, Lung cancer | 20 labelers | n/a | Yes | No current entry |
| Eribulinmicrotubule inhibitor | Breast cancer | 14 labelers | n/a | No | No current entry |
| Trastuzumabher2/neu receptor antagonist | Breast cancer | none listed | n/a | Yes | No current entry |
| Margetuximabher2/neu receptor antagonist | Breast cancer | none listed | n/a | Yes | No current entry |
| Trastuzumab emtansine | Breast cancer | none listed | n/a | Yes | No current entry |
| Trastuzumab-strfher2/neu receptor antagonist | Breast cancer | none listed | n/a | Yes | No current entry |
| Datopotamab deruxtecan | Breast cancer, Lung cancer | none listed | n/a | No | No current entry |
| Pembrolizumabprogrammed death receptor-1 blocking antibody | Breast cancer, Lung cancer | none listed | n/a | No | No current entry |
| Trastuzumab deruxtecan | Breast cancer, Lung cancer | none listed | n/a | Yes | No current entry |
| Fulvestrantestrogen receptor antagonist | Breast cancer | 1 labeler | n/a | No | A presentation being discontinued |
| Ixabepilone | Breast cancer | none listed | n/a | Yes | No current entry |
| Pertuzumabher2/neu receptor antagonist | Breast cancer | none listed | n/a | Yes | No current entry |
| Sacituzumab govitecan | Breast cancer | none listed | n/a | Yes | No current entry |
Source: FDA drug labels (indications) via openFDA; FDA NDC Directory; CMS NADAC of October 7, 2026; FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Gemcitabine: the full record
- label, generics, price, shortages, recalls
- Gemcitabine vs paclitaxel
- two records side by side